3p88: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==FXR bound to isoquinolinecarboxylic acid== | |||
=== | <StructureSection load='3p88' size='340' side='right' caption='[[3p88]], [[Resolution|resolution]] 2.95Å' scene=''> | ||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3p88]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3P88 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3P88 FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=P88:7-(4-{[3-(2,6-DIMETHYLPHENYL)-5-(1-METHYLETHYL)ISOXAZOL-4-YL]METHOXY}PHENYL)ISOQUINOLINE-3-CARBOXYLIC+ACID'>P88</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3p89|3p89]]</td></tr> | |||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hCG_20893, NR1H4 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]), BHLHE74, NCOA1, SRC1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3p88 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3p88 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3p88 RCSB], [http://www.ebi.ac.uk/pdbsum/3p88 PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
To improve on the drug properties of GSK8062 1b, a series of heteroaryl bicyclic naphthalene replacements were prepared. The quinoline 1c was an equipotent FXR agonist with improved drug developability parameters relative to 1b. In addition, analog 1c lowered body weight gain and serum glucose in a DIO mouse model of diabetes. | |||
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.,Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, McFadyen RB, Miller AB, Mills WY, Navas F 3rd, Parks DJ, Smalley TL Jr, Spearing PK, Todd D, Williams SP, Wisely GB Bioorg Med Chem Lett. 2011 Feb 15;21(4):1206-13. Epub 2010 Dec 23. PMID:21256005<ref>PMID:21256005</ref> | |||
== | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | |||
==See Also== | |||
*[[Bile acid receptor|Bile acid receptor]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Deaton, D N | [[Category: Deaton, D N]] | ||
[[Category: Madauss, K P | [[Category: Madauss, K P]] | ||
[[Category: Williams, S P | [[Category: Williams, S P]] | ||
[[Category: Nuclear recptor fxr]] | [[Category: Nuclear recptor fxr]] | ||
[[Category: Transcription-inhibitor complex]] | [[Category: Transcription-inhibitor complex]] |